Creative Medical Technology Holdings, Inc. (CELZ) vs Cadrenal Therapeutics, Inc. Common Stock (CVKD)

A side-by-side comparison of Creative Medical Technology Holdings, Inc. and Cadrenal Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Creative Medical Technology Holdings, Inc. logo
CELZ
Creative Medical Technology Holdings, Inc.
$2M
$0.92HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Cadrenal Therapeutics, Inc. Common Stock logo
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$3M
$0.95HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — CELZ vs CVKD

growth of $100 · dividends reinvested · last 4y
CELZ -82.0% (-34.9%/yr)CVKD -98.5% (-64.8%/yr)CELZ compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100202420252026$18$2
CELZ CVKD

CELZ vs CVKD: by the numbers

  • •CVKD is the larger company ($3M vs $2M market cap).
  • •Both run net losses; CVKD's is the smaller (0.00% vs -201355.37% net margin).

Metrics side by side

Valuation

MetricCELZCVKD
P/S ratio791.40N/A
P/B ratio0.270.82

Profitability

MetricCELZCVKD
Gross margin63.43%0.00%
Operating margin-102380.23%0.00%
Net margin-201355.37%0.00%
ROE-69.79%-282.13%
ROIC-71.90%-284.81%

Growth (annualized)

MetricCELZCVKD
Revenue CAGR (5Y)-50.85%N/A
Total return CAGR (5Y)-57.96%N/A

Go deeper

Full CELZ analysisFull CVKD analysisInteractive comparison tool

Dig into the metrics

Creative Medical Technology ROECadrenal Therapeutics, Inc. Common Stock ROECreative Medical Technology operating marginCadrenal Therapeutics, Inc. Common Stock operating marginCreative Medical Technology revenue growthCadrenal Therapeutics, Inc. Common Stock revenue growthCreative Medical Technology free cash flowCadrenal Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.